Verona Pharma (VRNA) Financials

$58.47 +0.66 (+1.14%)

Closing price 04:00 PM Eastern

Extended Trading

$58.07 -0.40 (-0.68%)

As of 07:39 PM Eastern

Annual Income Statements for Verona Pharma

This table shows Verona Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-11	-6.19	-28	-25	-41	-65	-56	-69	-54	-173
Consolidated Net Income / (Loss)	-11	-6.19	-28	-25	-41	-65	-56	-69	-54	-173
Net Income / (Loss) Continuing Operations	-11	-6.19	-28	-25	-41	-65	-56	-69	-54	-173
Total Pre-Tax Income	-13	-7.37	-34	-31	-40	-65	-56	-68	-54	-163
Total Operating Income	-13	-8.66	-40	-33	-52	-74	-73	-76	-68	-155
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	40	0.46	0.00	42
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	40	0.46	0.00	42
Operating Revenue	-	-	-	-	-	0.00	40	0.46	0.00	42
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	13	8.66	40	33	52	74	113	76	68	197
Selling, General & Admin Expense	2.51	3.08	8.16	8.02	9.99	30	34	27	50	152
Research & Development Expense	11	5.58	32	25	42	45	79	49	17	45
Total Other Income / (Expense), net	-0.04	1.29	6.15	1.86	12	9.28	18	7.30	14	-8.50
Interest Expense	0.11	0.98	3.33	1.69	0.00	0.04	0.34	1.34	2.06	27
Interest & Investment Income	0.07	2.27	9.48	3.55	0.96	0.12	0.01	2.82	13	15
Other Income / (Expense), net	-	-	-	-	11	9.19	18	5.82	2.97	3.43
Income Tax Expense	-2.22	-1.18	-6.36	-5.39	0.07	0.15	-0.02	0.25	0.47	10
Basic Earnings per Share	($37.10)	($0.15)	($23.40)	($18.90)	($0.39)	($0.25)	($0.12)	($0.13)	($0.09)	($0.27)
Weighted Average Basic Shares Outstanding	-	-	105.02M	105.33M	105.33M	463.48M	482.94M	529.07M	634.14M	652.31M
Diluted Earnings per Share	($37.10)	($0.15)	($23.40)	($18.90)	($0.39)	($0.25)	($0.12)	($0.13)	($0.09)	($0.27)
Weighted Average Diluted Shares Outstanding	-	-	105.02M	105.33M	105.33M	463.48M	482.94M	529.07M	634.14M	652.31M
Weighted Average Basic & Diluted Shares Outstanding	-	-	105.02M	105.33M	105.33M	463.48M	482.94M	631.90M	646.52M	679.83M

This table shows Verona Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-16	-10	-17	-8.81	-15	-14	-26	-71	-43	-34
Consolidated Net Income / (Loss)	-16	-10	-17	-8.81	-15	-14	-26	-71	-43	-34
Net Income / (Loss) Continuing Operations	-16	-10	-17	-8.81	-15	-14	-26	-71	-43	-34
Total Pre-Tax Income	-16	-10	-17	-8.50	-15	-14	-25	-70	-43	-26
Total Operating Income	-15	-15	-22	-9.97	-16	-19	-27	-68	-41	-18
Total Gross Profit	0.00	0.46	0.00	0.00	0.00	-	0.00	0.00	5.62	37
Total Revenue	0.00	0.46	0.00	0.00	0.00	-	0.00	0.00	5.62	37
Total Operating Expenses	15	16	22	9.97	16	19	27	68	46	55
Selling, General & Admin Expense	5.29	8.67	9.59	12	13	15	20	49	36	47
Research & Development Expense	9.84	6.84	13	-2.47	2.96	4.12	6.76	19	11	7.87
Total Other Income / (Expense), net	-0.46	4.63	5.63	1.47	1.67	4.91	2.16	-1.40	-2.05	-7.22
Interest Expense	0.12	1.05	0.29	0.74	0.40	0.62	1.59	5.41	9.88	10
Interest & Investment Income	0.78	1.86	2.68	3.40	3.39	3.29	3.38	3.14	4.75	3.99
Other Income / (Expense), net	-1.12	3.81	3.25	-1.19	-1.32	2.24	0.37	0.87	3.09	-0.89
Income Tax Expense	0.06	0.03	0.17	0.31	0.04	-0.05	0.75	1.01	0.25	8.27
Basic Earnings per Share	($0.03)	($0.01)	($0.03)	($0.01)	($0.02)	($0.03)	($0.04)	($0.11)	($0.07)	($0.05)
Weighted Average Basic Shares Outstanding	544.13M	529.07M	621.45M	634.47M	638.24M	634.14M	645.70M	648.22M	651.94M	652.31M
Diluted Earnings per Share	($0.03)	($0.01)	($0.03)	($0.01)	($0.02)	($0.03)	($0.04)	($0.11)	($0.07)	($0.05)
Weighted Average Diluted Shares Outstanding	544.13M	529.07M	621.45M	634.47M	638.24M	634.14M	645.70M	648.22M	651.94M	652.31M
Weighted Average Basic & Diluted Shares Outstanding	604.98M	631.90M	635.67M	635.88M	639.52M	646.52M	648.65M	649.88M	654.65M	679.83M

This table details how cash moves in and out of Verona Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-9.50	44	-9.35	-16	5.19	158	-40	79	44	128
Net Cash From Operating Activities	9.37	-6.89	28	23	-43	-45	-33	-60	-50	-122
Net Cash From Continuing Operating Activities	-9.37	-6.89	-28	-23	-43	-45	-33	-60	-50	-122
Net Income / (Loss) Continuing Operations	-13	-7.37	-34	-31	-41	-65	-56	-69	-54	-173
Consolidated Net Income / (Loss)	-13	-7.37	-34	-31	-41	-65	-56	-69	-54	-173
Depreciation Expense	0.01	0.01	0.01	0.01	0.51	0.62	0.63	0.64	0.68	1.06
Amortization Expense	0.06	0.06	0.16	0.11	0.00	0.02	0.24	0.19	0.22	1.42
Non-Cash Adjustments To Reconcile Net Income	1.95	-2.81	-2.42	1.02	1.45	22	8.00	19	17	56
Changes in Operating Assets and Liabilities, net	1.88	3.21	8.35	6.52	-4.27	-2.11	13	-11	-14	-6.84
Net Cash From Investing Activities	-0.14	-0.05	-67	6.73	47	9.71	-0.01	-0.03	0.00	-0.58
Net Cash From Continuing Investing Activities	-0.14	-0.05	-67	6.73	47	9.71	-0.01	-0.03	0.00	-0.58
Purchase of Property, Plant & Equipment	-0.00	-0.02	-0.01	-0.34	-0.05	-0.08	-0.01	-0.03	0.00	-0.58
Net Cash From Financing Activities	0.00	51	85	0.00	0.00	192	-6.12	141	93	251
Net Cash From Continuing Financing Activities	0.00	51	85	0.00	0.00	192	-6.12	141	93	251
Repayment of Debt	-	-	0.00	0.00	0.00	-0.11	0.00	-6.10	29	-59
Repurchase of Common Equity	-	-0.78	-	0.00	0.00	-13	0.00	-9.53	0.00	0.00
Issuance of Debt	-	-	-	-	0.00	5.00	0.00	10	10.00	123
Issuance of Common Equity	0.00	55	85	0.00	0.00	200	0.73	150	57	97
Other Financing Activities, net	0.00	-3.59	-	-	0.00	0.04	-6.85	-3.35	-2.74	90
Effect of Exchange Rate Changes	-	-	-	-	0.74	0.58	-0.22	-1.48	1.30	-0.01
Cash Interest Paid	-	-	-	-	0.00	0.01	0.22	0.35	2.01	10
Cash Income Taxes Paid	-	-	-	-	0.00	0.01	0.00	0.12	1.25	0.64

This table details how cash moves in and out of Verona Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	120	-3.87	64	-21	-13	14	-17	150	-69	64
Net Cash From Operating Activities	-18	-7.74	-5.78	-21	-13	-10	-14	-17	-63	-29
Net Cash From Continuing Operating Activities	-18	-7.74	-5.78	-21	-13	-10	-14	-17	-63	-29
Net Income / (Loss) Continuing Operations	-16	-10	-17	-8.81	-15	-14	-26	-71	-43	-34
Consolidated Net Income / (Loss)	-16	-10	-17	-8.81	-15	-14	-26	-71	-43	-34
Depreciation Expense	0.16	0.15	0.16	0.16	0.16	0.21	0.26	0.27	0.27	0.26
Amortization Expense	0.05	0.03	0.09	0.05	0.05	0.04	0.17	0.23	0.49	0.53
Non-Cash Adjustments To Reconcile Net Income	6.67	2.03	3.36	4.33	6.09	3.36	4.48	41	-9.63	20
Changes in Operating Assets and Liabilities, net	-9.32	0.50	7.36	-17	-4.33	0.12	7.27	13	-11	-16
Net Cash From Investing Activities	-	-	0.00	-	-	-	-0.02	-0.03	-	-0.54
Net Cash From Continuing Investing Activities	-	-	0.00	-	-	-	-0.02	-0.03	-	-0.54
Purchase of Property, Plant & Equipment	-	-	0.00	-	-	-	-0.02	-0.03	-	-0.54
Net Cash From Financing Activities	140	2.61	69	0.12	0.05	24	-3.12	167	-7.09	94
Net Cash From Continuing Financing Activities	140	2.61	69	0.12	0.05	24	-3.12	167	-7.09	94
Issuance of Common Equity	150	-	57	0.05	-	-	0.00	-	-	97
Other Financing Activities, net	-0.53	-1.34	1.83	0.08	0.05	-4.69	-2.76	99	-2.48	-3.34
Effect of Exchange Rate Changes	-1.33	1.25	0.69	0.50	-0.68	0.80	-0.14	0.02	1.18	-1.07
Cash Interest Paid	0.08	0.16	0.24	0.44	0.54	0.78	0.93	1.09	4.43	3.88
Cash Income Taxes Paid	0.09	0.03	-	-	-	0.03	-	-	0.25	0.39

This table presents Verona Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	57	121	95	56	204	187	259	308	474
Total Current Assets	54	118	91	54	203	0.00	243	290	454
Cash & Equivalents	49	42	25	30	188	-	228	272	400
Accounts Receivable	-	-	-	-	-	-	-	0.00	31
Inventories, net	-	-	-	-	-	-	-	0.00	6.25
Prepaid Expenses	3.65	2.45	3.14	1.66	4.54	-	2.50	3.62	7.57
Current Deferred & Refundable Income Taxes	1.32	6.76	5.73	9.81	8.26	-	9.28	11	5.76
Other Current Assets	-	-	-	2.02	1.72	-	3.39	3.37	2.74
Plant, Property, & Equipment, net	0.02	0.02	0.03	0.06	0.11	0.00	0.07	0.02	1.11
Total Noncurrent Assets	2.86	3.26	3.90	1.87	1.60	0.55	16	18	20
Goodwill	0.54	0.60	0.56	0.59	0.55	0.55	0.55	0.55	0.55
Other Noncurrent Operating Assets	-	-	0.00	1.29	1.05	-	16	18	19
Total Liabilities & Shareholders' Equity	57	121	95	56	204	0.00	259	308	474
Total Liabilities	14	13	14	13	19	0.00	29	59	270
Total Current Liabilities	13	12	13	13	14	0.00	19	8.69	43
Accounts Payable	3.48	9.66	9.85	1.93	0.18	-	2.91	3.49	11
Accrued Expenses	-	-	-	8.97	11	-	14	3.59	17
Current Deferred & Payable Income Tax Liabilities	0.16	0.23	-	-	0.00	-	0.28	0.00	8.89
Other Current Liabilities	-	-	0.00	1.94	3.16	-	2.08	1.62	5.77
Total Noncurrent Liabilities	0.99	1.39	1.40	0.65	5.15	0.00	9.97	50	227
Long-Term Debt	-	-	-	0.00	4.64	-	9.77	48	120
Other Noncurrent Operating Liabilities	0.99	1.18	1.27	0.65	0.51	-	0.21	1.78	107
Commitments & Contingencies	-	-	-	0.00	0.00	-	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	43	108	81	43	185	0.00	230	249	205
Total Preferred & Common Equity	43	108	81	43	185	0.00	230	249	205
Total Common Equity	43	108	81	43	185	0.00	230	249	205
Common Stock	75	168	158	187	398	-	570	644	773
Retained Earnings	-35	-67	-87	-142	-207	-	-333	-388	-562
Treasury Stock	-	-	-	0.00	-1.70	-	-1.55	-1.52	-1.66
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-2.28	-4.60	-	-4.60	-4.60	-4.60

This table presents Verona Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	275	323	304	292	290	434	382
Total Current Assets	0.00	0.00	288	277	272	416	364
Cash & Equivalents	-	-	271	257	255	405	336
Accounts Receivable	-	-	-	-	-	-	6.90
Inventories, net	-	-	-	-	-	-	4.32
Prepaid Expenses	-	-	0.89	3.33	3.62	5.43	7.96
Current Deferred & Refundable Income Taxes	-	-	10	9.51	11	3.68	5.59
Other Current Assets	-	-	6.06	6.32	1.88	2.58	3.44
Plant, Property, & Equipment, net	0.00	0.00	0.01	0.01	0.02	0.04	0.04
Total Noncurrent Assets	0.54	0.55	16	16	18	18	18
Goodwill	0.54	0.55	0.55	0.55	0.55	0.55	0.55
Other Noncurrent Operating Assets	-	-	16	15	18	17	17
Total Liabilities & Shareholders' Equity	0.00	0.00	304	292	290	434	382
Total Liabilities	0.00	0.00	31	29	65	266	251
Total Current Liabilities	0.00	0.00	11	9.01	15	48	28
Accounts Payable	-	-	2.49	0.82	4.65	4.15	6.83
Accrued Expenses	-	-	7.47	7.40	8.27	20	18
Current Deferred & Payable Income Tax Liabilities	-	-	0.00	0.00	-	1.01	1.01
Other Current Liabilities	-	-	0.99	0.79	1.85	24	1.97
Total Noncurrent Liabilities	0.00	0.00	20	20	50	218	223
Long-Term Debt	-	-	20	20	49	120	120
Other Noncurrent Operating Liabilities	-	-	0.03	0.02	1.60	98	103
Commitments & Contingencies	-	-	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	0.00	0.00	273	264	225	168	130
Total Preferred & Common Equity	0.00	0.00	273	264	225	168	130
Total Common Equity	0.00	0.00	273	264	225	168	130
Common Stock	-	-	638	643	645	659	664
Retained Earnings	-	-	-359	-374	-414	-485	-528
Treasury Stock	-	-	-0.98	-0.75	-1.28	-1.20	-0.83
Accumulated Other Comprehensive Income / (Loss)	-	-	-4.60	-4.60	-4.60	-4.60	-4.60

This table displays calculated financial ratios and metrics derived from Verona Pharma's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-98.86%	-100.00%	0.00%
EBITDA Growth	0.00%	34.71%	-366.28%	18.87%	-26.07%	-57.40%	15.60%	-27.06%	7.83%	-133.46%
EBIT Growth	0.00%	34.52%	-364.08%	18.89%	-27.15%	-57.01%	15.10%	-26.55%	7.63%	-134.05%
NOPAT Growth	0.00%	34.52%	-364.08%	18.89%	-60.73%	-41.74%	1.30%	-3.32%	10.80%	-128.84%
Net Income Growth	0.00%	43.94%	-347.13%	8.44%	-59.98%	-60.61%	14.70%	-23.63%	20.86%	-218.96%
EPS Growth	0.00%	99.60%	-15,500.00%	19.23%	97.94%	35.90%	52.00%	-8.33%	30.77%	-200.00%
Operating Cash Flow Growth	0.00%	-173.58%	505.64%	-17.47%	-285.79%	-5.15%	26.23%	-80.01%	16.10%	-143.33%
Free Cash Flow Firm Growth	0.00%	0.00%	-181.54%	11.38%	-60.13%	-39.07%	2.33%	-28.84%	6.34%	87.66%
Invested Capital Growth	0.00%	0.00%	-62.54%	27.61%	25.71%	-22.25%	-63.74%	2,176.51%	108.63%	-389.19%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	651.76%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.48%	14.96%	-9.54%	-1.25%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.36%	14.84%	-9.52%	-1.60%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1.05%	15.05%	-6.37%	0.49%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.75%	15.72%	-7.26%	-12.81%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-50.00%	18.75%	-28.57%	-8.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.24%	13.80%	-5.60%	-17.76%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-14.87%	13.17%	-363.55%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-91.58%	2,180.70%	-0.72%	12.49%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	100.00%	0.00%	100.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-135.98%	-15,089.30%	0.00%	-351.74%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-183.28%	-16,539.30%	0.00%	-365.73%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-138.15%	-15,269.21%	0.00%	-357.61%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-138.92%	-15,000.22%	0.00%	-410.18%
Tax Burden Percent	83.24%	84.03%	81.33%	82.46%	100.18%	100.22%	99.97%	100.37%	100.88%	106.31%
Interest Burden Percent	100.31%	85.09%	84.70%	94.30%	97.67%	99.87%	100.59%	97.88%	83.43%	107.89%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-5,011.63%	-818.79%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-5,006.98%	-804.38%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4,951.51%	759.17%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-14.56%	-36.81%	-26.87%	-65.67%	-57.25%	-60.12%	-59.62%	-22.67%	-76.42%
Cash Return on Invested Capital (CROIC)	0.00%	-576.99%	-1,181.75%	-1,688.45%	-2,136.60%	-3,001.39%	-4,918.08%	-1,001.96%	-317.44%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-28.28%	-31.36%	0.00%	-38.65%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-28.44%	-30.80%	0.00%	-44.33%
Return on Common Equity (ROCE)	0.00%	-14.56%	-36.81%	-26.87%	-65.67%	-57.25%	-60.12%	-59.62%	-22.67%	-76.42%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-14.56%	-25.66%	-31.38%	-94.90%	-35.24%	0.00%	-29.81%	-21.81%	-84.78%
Net Operating Profit after Tax (NOPAT)	-9.26	-6.06	-28	-23	-37	-52	-51	-53	-47	-108
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-128.30%	-11,577.51%	0.00%	-256.01%
Net Nonoperating Expense Percent (NNEP)	0.00%	-0.66%	0.61%	-2.72%	-6.46%	-11.73%	-4.65%	-14.41%	-3.20%	-25.93%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-22.07%	-15.89%	-33.31%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	84.77%	5,878.82%	0.00%	360.30%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	198.52%	10,760.48%	0.00%	105.43%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	283.28%	16,639.30%	0.00%	465.73%
Earnings before Interest and Taxes (EBIT)	-13	-8.66	-40	-33	-41	-65	-55	-70	-65	-151
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-13	-8.59	-40	-32	-41	-64	-54	-69	-64	-149
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	1.57	1.77	0.50	0.00	8.57	6.38	18.58
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	1.65	1.80	0.50	0.00	8.59	6.39	18.63
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	10.08	4,314.45	0.00	89.88
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	30.84	18.05	0.00	739.94	141.69	52.76	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	10.08	3,838.34	0.00	83.28
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	2.06	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.04	0.00	0.03	0.00	0.04	0.19	0.59
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.03	0.00	0.04	0.19	0.59
Financial Leverage	0.00	-0.92	-0.97	-0.99	-0.97	-0.98	-0.99	-0.94	-0.92	-1.11
Leverage Ratio	0.00	1.34	1.18	1.15	1.23	1.14	2.11	1.94	1.18	1.72
Compound Leverage Factor	0.00	1.14	1.00	1.08	1.20	1.14	2.13	1.89	0.99	1.86
Debt to Total Capital	0.00%	0.00%	0.00%	3.78%	0.00%	2.45%	0.00%	4.07%	16.25%	37.04%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	3.78%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	2.45%	0.00%	4.07%	16.25%	37.04%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	100.00%	100.00%	96.22%	100.00%	97.55%	0.00%	95.93%	83.75%	62.96%
Debt to EBITDA	0.00	0.00	0.00	-0.10	0.00	-0.07	0.00	-0.14	-0.76	-0.81
Net Debt to EBITDA	0.00	0.00	0.00	2.44	0.00	2.85	0.00	3.16	3.51	1.88
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	-0.07	0.00	-0.14	-0.76	-0.81
Debt to NOPAT	0.00	0.00	0.00	-0.14	0.00	-0.09	0.00	-0.18	-1.02	-1.11
Net Debt to NOPAT	0.00	0.00	0.00	3.47	0.00	3.53	0.00	4.11	4.72	2.58
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	-0.09	0.00	-0.18	-1.02	-1.11
Altman Z-Score	0.00	0.00	0.00	3.84	-1.71	1.49	0.00	39.23	14.84	6.87
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	4.03	10.13	7.01	4.23	14.26	0.00	12.77	33.33	10.63
Quick Ratio	0.00	3.66	9.34	6.33	3.18	13.24	0.00	11.97	31.27	10.10
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-9.28	-26	-23	-37	-52	-50	-65	-61	-7.50
Operating Cash Flow to CapEx	635,483.57%	-42,969.36%	229,955.74%	6,757.83%	-80,883.02%	-54,970.73%	-277,116.67%	-206,420.69%	0.00%	-21,069.48%
Free Cash Flow to Firm to Interest Expense	0.00	-9.47	-7.85	-13.72	0.00	-1,473.25	-148.12	-48.57	-29.55	-0.28
Operating Cash Flow to Interest Expense	87.07	-7.04	8.40	13.67	0.00	-1,287.89	-97.81	-44.81	-24.42	-4.49
Operating Cash Flow Less CapEx to Interest Expense	87.06	-7.05	8.39	13.47	0.00	-1,290.23	-97.84	-44.83	-24.42	-4.51
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.00	0.00	0.11
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	74.90
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	3.22	1.20	1.54	1.93	1.50	0.55	12	26	-75
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	39.06	0.07	0.00	-1.73
Increase / (Decrease) in Invested Capital	0.00	3.22	-2.01	0.33	0.40	-0.43	-0.96	12	13	-101
Enterprise Value (EV)	0.00	0.00	0.00	47	35	-91	403	1,758	1,366	3,521
Market Capitalization	0.00	0.00	0.00	127	76	92	403	1,976	1,589	3,800
Book Value per Share	$0.00	$0.00	$1.03	$0.77	$0.41	$1.76	$0.00	$0.38	$0.39	$0.31
Tangible Book Value per Share	$0.00	$0.00	$1.00	$0.73	$0.40	$1.75	$0.00	$0.38	$0.39	$0.31
Total Capital	0.00	43	108	84	43	189	0.00	240	298	325
Total Debt	0.00	0.00	0.00	3.17	0.00	4.64	0.00	9.77	48	120
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	4.64	0.00	9.77	48	120
Net Debt	0.00	-49	-108	-79	-41	-183	0.00	-218	-223	-279
Capital Expenditures (CapEx)	0.00	0.02	0.01	0.34	0.05	0.08	0.01	0.03	0.00	0.58
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-8.45	-2.40	-0.98	0.65	0.32	0.00	-3.86	9.24	11
Debt-free Net Working Capital (DFNWC)	0.00	41	106	81	41	188	0.00	224	281	411
Net Working Capital (NWC)	0.00	41	106	78	41	188	0.00	224	281	411
Net Nonoperating Expense (NNE)	1.79	0.13	-0.45	2.53	3.88	13	4.25	16	7.07	65
Net Nonoperating Obligations (NNO)	0.00	-39	-107	-79	-41	-183	0.55	-218	-223	-279
Total Depreciation and Amortization (D&A)	0.08	0.08	0.17	0.12	0.51	0.64	0.87	0.82	0.90	2.48
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-842.79%	0.00%	26.33%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	48,901.09%	0.00%	971.86%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	48,901.09%	0.00%	971.86%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($23.40)	($0.19)	($30.30)	($0.25)	($0.12)	($0.13)	($0.09)	($0.27)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	105.02M	105.33M	105.33M	463.48M	482.94M	631.90M	634.14M	652.31M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($23.40)	($0.19)	($30.30)	($0.25)	($0.12)	($0.13)	($0.09)	($0.27)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	105.02M	105.33M	105.33M	463.48M	482.94M	631.90M	634.14M	652.31M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($23.40)	($0.19)	($30.30)	($0.25)	($0.12)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	105.02M	105.33M	105.33M	463.48M	482.94M	631.90M	646.52M	679.83M
Normalized Net Operating Profit after Tax (NOPAT)	-9.26	-6.06	-28	-23	-37	-52	-51	-53	-47	-108
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-128.30%	-11,577.51%	0.00%	-256.01%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-138.97%	-14,944.98%	0.00%	-385.84%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-122.96	-8.84	-12.07	-19.31	0.00	-1,859.60	-162.53	-52.35	-31.40	-5.56
NOPAT to Interest Expense	-86.07	-6.19	-8.45	-13.52	0.00	-1,485.54	-150.94	-39.69	-22.99	-3.98
EBIT Less CapEx to Interest Expense	-122.97	-8.86	-12.08	-19.52	0.00	-1,861.94	-162.57	-52.37	-31.40	-5.58
NOPAT Less CapEx to Interest Expense	-86.09	-6.21	-8.45	-13.72	0.00	-1,487.88	-150.97	-39.71	-22.99	-4.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-12.67%	0.00%	0.00%	0.00%	-19.57%	0.00%	-13.88%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Verona Pharma's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-239.73%	52.35%	23.55%	37.56%	-8.69%	-50.16%	-41.12%	-512.09%	-111.27%	-11.05%
EBIT Growth	-244.28%	52.03%	23.22%	37.17%	-8.53%	-49.95%	-41.56%	-505.35%	-113.14%	-14.12%
NOPAT Growth	-263.36%	47.13%	11.43%	51.41%	-7.82%	-26.88%	-22.52%	-586.63%	-149.32%	3.95%
Net Income Growth	-241.59%	55.07%	32.59%	50.43%	6.14%	-35.22%	-54.06%	-704.30%	-192.52%	-139.36%
EPS Growth	-250.00%	75.00%	40.00%	75.00%	33.33%	-200.00%	-33.33%	-1,000.00%	-250.00%	-66.67%
Operating Cash Flow Growth	-179.28%	55.33%	60.16%	-9.19%	29.67%	-34.43%	-135.39%	19.75%	-392.30%	-177.22%
Free Cash Flow Firm Growth	-71,733.34%	-18.07%	-106.84%	-345.49%	-693.23%	-19.86%	-110.90%	466.09%	325.05%	427.47%
Invested Capital Growth	-91.60%	2,176.51%	135.64%	410.76%	4,692.65%	108.63%	3,322.39%	-624.85%	-428.09%	-389.19%
Revenue Q/Q Growth	0.00%	0.00%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	551.76%
EBITDA Q/Q Growth	8.60%	31.01%	-69.10%	41.44%	-59.11%	4.69%	-58.91%	-154.00%	45.08%	49.90%
EBIT Q/Q Growth	8.53%	30.81%	-68.63%	41.13%	-58.01%	4.41%	-59.20%	-151.76%	44.37%	48.82%
NOPAT Q/Q Growth	26.23%	0.52%	-47.51%	55.11%	-63.68%	-17.06%	-42.44%	-151.57%	40.57%	54.90%
Net Income Q/Q Growth	11.93%	33.21%	-60.20%	47.40%	-66.77%	3.78%	-82.52%	-174.62%	39.35%	21.26%
EPS Q/Q Growth	25.00%	66.67%	-200.00%	66.67%	-100.00%	-50.00%	-33.33%	-175.00%	36.36%	28.57%
Operating Cash Flow Q/Q Growth	7.29%	57.24%	25.28%	-268.57%	40.28%	18.27%	-30.84%	-25.66%	-266.36%	53.98%
Free Cash Flow Firm Q/Q Growth	16.49%	-380.85%	21.36%	-41.07%	-48.69%	27.34%	-38.38%	344.89%	-8.60%	5.72%
Invested Capital Q/Q Growth	-87.50%	2,180.70%	-95.61%	3,977.61%	17.32%	-0.72%	-27.94%	-725.34%	26.66%	12.49%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	100.00%
EBITDA Margin	0.00%	-2,415.28%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-654.73%	-50.33%
Operating Margin	0.00%	-3,285.81%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-723.10%	-50.03%
EBIT Margin	0.00%	-2,454.15%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-668.21%	-52.47%
Profit (Net Income) Margin	0.00%	-2,281.88%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-763.90%	-92.28%
Tax Burden Percent	100.41%	100.27%	101.04%	103.65%	100.30%	99.63%	103.01%	101.45%	100.59%	132.36%
Interest Burden Percent	95.92%	92.73%	87.42%	76.14%	83.05%	84.16%	93.32%	103.36%	113.66%	132.88%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-162.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-162.74%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	153.60%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-96.92%	-9.07%	-95.97%	0.00%	0.00%	-22.67%	-56.38%	-56.85%	-78.03%	-76.42%
Cash Return on Invested Capital (CROIC)	-1,609.26%	-1,001.96%	-9,741.80%	-462.94%	-525.96%	-317.44%	-717.87%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-5.04%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-11.15%	-5.67%
Return on Assets (ROA)	0.00%	-4.69%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-12.74%	-9.97%
Return on Common Equity (ROCE)	-96.92%	-9.07%	-95.97%	0.00%	0.00%	-22.67%	-56.38%	-56.85%	-78.03%	-76.42%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	0.00%	-18.91%	-19.23%	0.00%	-28.19%	-74.55%	-117.80%	0.00%
Net Operating Profit after Tax (NOPAT)	-11	-11	-16	-6.98	-11	-13	-19	-48	-28	-13
NOPAT Margin	0.00%	-2,300.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-506.17%	-35.02%
Net Nonoperating Expense Percent (NNEP)	-6.28%	0.08%	-1.89%	-1.02%	-2.76%	-0.35%	-6.57%	-8.56%	-6.39%	-8.35%
Return On Investment Capital (ROIC_SIMPLE)	-	-4.39%	-	-	-	-4.49%	-	-	-	-3.95%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	1,892.79%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	635.47%	128.56%
R&D to Revenue	0.00%	1,493.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	187.62%	21.47%
Operating Expenses to Revenue	0.00%	3,385.81%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	823.10%	150.03%
Earnings before Interest and Taxes (EBIT)	-16	-11	-19	-11	-18	-17	-27	-68	-38	-19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-16	-11	-19	-11	-17	-17	-26	-67	-37	-18
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	8.57	0.00	6.15	4.92	6.38	5.78	6.97	17.91	18.58
Price to Tangible Book Value (P/TBV)	0.00	8.59	0.00	6.16	4.93	6.39	5.79	6.99	17.99	18.63
Price to Revenue (P/Rev)	0.00	4,314.45	3,463.06	3,667.58	2,828.81	0.00	0.00	0.00	415.56	89.88
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1,145.13	141.69	2,910.24	64.30	40.59	52.76	58.65	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	3,838.34	3,463.06	3,119.83	2,310.34	0.00	0.00	0.00	377.15	83.28
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	18.83	745.66	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.04	0.00	0.07	0.08	0.19	0.22	0.71	0.92	0.59
Long-Term Debt to Equity	0.00	0.04	0.00	0.07	0.08	0.19	0.22	0.71	0.92	0.59
Financial Leverage	-0.96	-0.94	-1.01	-0.93	-0.90	-0.92	-0.91	-1.21	-1.15	-1.11
Leverage Ratio	2.83	1.94	3.90	1.19	2.15	1.18	2.72	1.67	1.71	1.72
Compound Leverage Factor	2.72	1.79	3.41	0.91	1.79	1.00	2.54	1.73	1.95	2.29
Debt to Total Capital	0.00%	4.07%	0.00%	6.78%	7.02%	16.25%	17.75%	41.56%	47.91%	37.04%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	4.07%	0.00%	6.78%	7.02%	16.25%	17.75%	41.56%	47.91%	37.04%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	95.93%	0.00%	93.22%	92.98%	83.75%	82.25%	58.44%	52.09%	62.96%
Debt to EBITDA	0.00	-0.14	0.00	-0.35	-0.34	-0.76	-0.68	-0.94	-0.82	-0.81
Net Debt to EBITDA	0.00	3.16	0.00	4.42	4.08	3.51	2.89	2.23	1.47	1.88
Long-Term Debt to EBITDA	0.00	-0.14	0.00	-0.35	-0.34	-0.76	-0.68	-0.94	-0.82	-0.81
Debt to NOPAT	0.00	-0.18	0.00	-0.46	-0.45	-1.02	-0.96	-1.30	-1.10	-1.11
Net Debt to NOPAT	0.00	4.11	0.00	5.75	5.34	4.72	4.06	3.11	1.99	2.58
Long-Term Debt to NOPAT	0.00	-0.18	0.00	-0.46	-0.45	-1.02	-0.96	-1.30	-1.10	-1.11
Altman Z-Score	0.00	39.98	0.00	32.00	25.97	15.35	10.77	1.58	4.39	7.79
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	12.77	0.00	26.29	30.68	33.33	18.40	8.61	13.03	10.63
Quick Ratio	0.00	11.97	0.00	24.73	28.56	31.27	17.25	8.37	12.27	10.10
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-4.66	-22	-18	-25	-37	-27	-37	91	83	88
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-85,062.50%	-58,972.41%	0.00%	-5,389.91%
Free Cash Flow to Firm to Interest Expense	-40.15	-21.43	-60.11	-33.58	-92.13	-43.09	-23.42	16.81	8.41	8.52
Operating Cash Flow to Interest Expense	-155.99	-7.40	-19.73	-28.80	-31.74	-16.70	-8.58	-3.16	-6.34	-2.80
Operating Cash Flow Less CapEx to Interest Expense	-155.99	-7.40	-19.73	-28.80	-31.74	-16.70	-8.59	-3.17	-6.34	-2.85
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.11
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	8.98	0.00	0.00	0.00	0.00	224.96	74.90
Accounts Payable Turnover	0.00	0.00	0.00	0.06	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	6,254.05	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	-6,254.05	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.54	12	0.55	22	26	26	19	-117	-86	-75
Invested Capital Turnover	0.00	0.07	-0.93	0.03	0.03	0.00	0.00	0.00	-0.19	-1.73
Increase / (Decrease) in Invested Capital	-5.93	12	2.07	18	26	13	18	-139	-112	-101
Enterprise Value (EV)	623	1,758	1,586	1,429	1,058	1,366	1,094	888	2,121	3,521
Market Capitalization	623	1,976	1,586	1,680	1,296	1,589	1,300	1,172	2,337	3,800
Book Value per Share	$0.00	$0.38	$0.00	$0.43	$0.41	$0.39	$0.35	$0.26	$0.20	$0.31
Tangible Book Value per Share	$0.00	$0.38	$0.00	$0.43	$0.41	$0.39	$0.35	$0.26	$0.20	$0.31
Total Capital	0.00	240	0.00	293	283	298	274	288	251	325
Total Debt	0.00	9.77	0.00	20	20	48	49	120	120	120
Total Long-Term Debt	0.00	9.77	0.00	20	20	48	49	120	120	120
Net Debt	0.00	-218	0.00	-251	-237	-223	-206	-285	-216	-279
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.03	0.00	0.54
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-3.86	0.00	6.16	10	9.24	2.18	-37	0.26	11
Debt-free Net Working Capital (DFNWC)	0.00	224	0.00	277	268	281	257	368	336	411
Net Working Capital (NWC)	0.00	224	0.00	277	268	281	257	368	336	411
Net Nonoperating Expense (NNE)	5.06	-0.08	1.20	1.83	3.27	0.77	6.76	23	14	21
Net Nonoperating Obligations (NNO)	0.54	-218	0.55	-251	-237	-223	-206	-285	-216	-279
Total Depreciation and Amortization (D&A)	0.21	0.18	0.25	0.21	0.20	0.24	0.44	0.50	0.76	0.79
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-842.79%	0.00%	1,343.89%	2,215.94%	0.00%	0.00%	0.00%	4.68%	26.33%
Debt-free Net Working Capital to Revenue	0.00%	48,901.09%	0.00%	60,454.59%	58,409.39%	0.00%	0.00%	0.00%	5,979.78%	971.86%
Net Working Capital to Revenue	0.00%	48,901.09%	0.00%	60,454.59%	58,409.39%	0.00%	0.00%	0.00%	5,979.78%	971.86%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.03)	($0.01)	($0.03)	($0.01)	($0.02)	($0.03)	($0.04)	($0.11)	($0.07)	($0.05)
Adjusted Weighted Average Basic Shares Outstanding	544.13M	529.07M	621.45M	634.47M	638.24M	634.14M	645.70M	648.22M	651.94M	652.31M
Adjusted Diluted Earnings per Share	($0.03)	($0.01)	($0.03)	($0.01)	($0.02)	($0.03)	($0.04)	($0.11)	($0.07)	($0.05)
Adjusted Weighted Average Diluted Shares Outstanding	544.13M	529.07M	621.45M	634.47M	638.24M	634.14M	645.70M	648.22M	651.94M	652.31M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	604.98M	631.90M	635.67M	635.88M	639.52M	646.52M	648.65M	649.88M	654.65M	679.83M
Normalized Net Operating Profit after Tax (NOPAT)	-11	-11	-16	-6.98	-11	-13	-19	-48	-28	-13
Normalized NOPAT Margin	0.00%	-2,300.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-506.17%	-35.02%
Pre Tax Income Margin	0.00%	-2,275.76%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-759.46%	-69.72%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-140.05	-10.76	-64.69	-15.08	-43.97	-27.05	-16.92	-12.49	-3.80	-1.86
NOPAT to Interest Expense	-91.29	-10.08	-53.04	-9.43	-28.47	-21.45	-12.00	-8.85	-2.88	-1.24
EBIT Less CapEx to Interest Expense	-140.05	-10.76	-64.69	-15.08	-43.97	-27.05	-16.93	-12.49	-3.80	-1.92
NOPAT Less CapEx to Interest Expense	-91.29	-10.08	-53.04	-9.43	-28.47	-21.45	-12.01	-8.86	-2.88	-1.30
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-11.76%	-13.88%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Verona Pharma's Financials

When does Verona Pharma's fiscal year end?

According to the most recent income statement we have on file, Verona Pharma's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Verona Pharma's net income changed over the last 9 years?

Verona Pharma's net income appears to be on an upward trend, with a most recent value of -$173.42 million in 2024, rising from -$11.05 million in 2015. The previous period was -$54.37 million in 2023.

What is Verona Pharma's operating income?

Verona Pharma's total operating income in 2024 was -$154.63 million, based on the following breakdown:

Total Gross Profit: $42.28 million
Total Operating Expenses: $196.91 million

How has Verona Pharma revenue changed over the last 9 years?

Over the last 9 years, Verona Pharma's total revenue changed from $0.00 in 2015 to $42.28 million in 2024, a change of 4,227,900,000.0%.

How much debt does Verona Pharma have?

Verona Pharma's total liabilities were at $269.68 million at the end of 2024, a 358.3% increase from 2023, and a 1,772.3% increase since 2016.

How much cash does Verona Pharma have?

In the past 8 years, Verona Pharma's cash and equivalents has ranged from $0.00 in 2021 to $399.76 million in 2024, and is currently $399.76 million as of their latest financial filing in 2024.

How has Verona Pharma's book value per share changed over the last 9 years?

Over the last 9 years, Verona Pharma's book value per share changed from 0.00 in 2015 to 0.31 in 2024, a change of 31.3%.

Remove Ads

Related Companies

This page (NASDAQ:VRNA) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verona Pharma (VRNA) Financials

Frequently Asked Questions About Verona Pharma's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verona Pharma (VRNA) Financials

Annual Income Statements for Verona Pharma

Quarterly Income Statements for Verona Pharma

Annual Cash Flow Statements for Verona Pharma

Quarterly Cash Flow Statements for Verona Pharma

Annual Balance Sheets for Verona Pharma

Quarterly Balance Sheets for Verona Pharma

Annual Metrics and Ratios for Verona Pharma

Quarterly Metrics and Ratios for Verona Pharma

Frequently Asked Questions About Verona Pharma's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools